Browse
You are looking at 51 - 60 of 89 items for :
- Policy/Advocacy x
- Refine by Content Type: News x
Department of Health and Human Services (HHS) officials from the office of the Secretary, office of the Chief Technology Officer (OTC), Centers for Medicare and Medicaid Services (CMS), and the Innovation Center at CMS, came together for an HHS-wide Forum on the Executive Order on Advancing American Kidney Health (AAKH), especially the Kidney Care Choices (KCC) model on Thursday, November 7, at Kidney Week 2019. The session was standing room only with a very engaged audience.
You can learn more about the KCC Model of the AAKH initiative by joining a series of webinars being hosted by the Center for Medicare and Medicaid Innovation (CMMI). CMMI will be hosting a series of webinars to introduce the details of the CMS Kidney Care First (KCF) and Comprehensive Kidney Care Contracting (CKCC) Model Options and review the application process, which closes on January 22, 2020. The webinars are:
"The American Society of Nephrology (ASN) welcomes the introduction of the voluntary Kidney Care Choices (KCC) Model, and its four kidney care payment options, addressing key aspects of the Executive Order on Advancing American Kidney Health (AAKH). This voluntary model will be a true game changer and brings desperately needed, sweeping changes to care for people with kidney diseases. ASN has long advocated for key elements of this model, and I thank HHS Secretary Azar and his entire team for putting forward such a visionary approach for the future of kidney care.
After a long period of consultation with ASN and others in the kidney community, Department of Health and Human Services (HHS) Secretary Alex M. Azar, II, yesterday unveiled the four voluntary kidney care payment options of the Kidney Care Choices ( KCC ) Model that are a part of the Advancing American Kidney Health (AAKH) initiative. ASN President Mark E. Rosenberg, MD, FASN, calls the AAKH initiative “a true game changer.”
In a joint letter to the Centers for Medicare and Medicaid Services Administrator (CMS) Seema Verma, ASN, the National Kidney Foundation (NKF), and the Renal Physicians Association (RPA) laud the Trump administration for its “ambitious agenda for kidney health” and identify five principles the organizations state will lead to “better patient outcomes that should be supported in the proposed ETC Model.”
Following a recent letter to the editor in the Kansas City Star , kidney patients continue to urge their congressional representatives to support KidneyX during the Senate appropriations process.
Cutessa Bourge, a kidney transplant recipient in Alabama, and Ann Rayburn, her Alabama kidney donor, called on Senator Richard Shelby (R-AL) to support the needs of the 645,665 patients with kidney disease in Alabama by supporting KidneyX in a new op-ed on Al.com . As Chairman of the Senate Appropriations Committee, Senator Shelby will have considerable influence on the Senate appropriations process. Ms. Bourge’s and Ms. Rayburn’s guest commentary piece can be viewed in its entirety here .
On Monday September 2nd, the Trump Administration announced a change to a policy that allowed immigrants to receive a temporary reprieve from deportation while receiving life-savings medical care in the US. In a joint statement from the American Society of Nephrology (ASN) and the American Society of Pediatric Nephrology (ASPN), the societies raised concerns about this the decision due to the harmful effect it will have on immigrants—children, their families, and adults—currently on dialysis treatment in the US.
The American Society of Nephrology (ASN) Department of Policy and Public Affairs team has received numerous questions from interested members and from the broader kidney community on the recent
Executive Order on Advancing American Kidney Health
and the accompanying
Department of Health and Human Services report
highlighting specific initiatives. In order to engage with our members, we will be running a series in Kidney News Online that addresses these questions. This is the second piece in that series.
According to the statement released by the American Society of Transplantation (AST):
“The Food and Drug Administration (FDA) and the American Society of Hospital Pharmacists (ASHP) recently published data on shortages of tacrolimus, an anti-rejection medicine used to prevent rejection after organ transplantation. At the time this information was published, these shortages apply to some generic versions of tacrolimus, and dates for resolution of the shortages range from July 2019 to April 2020. Generic formulations have been evaluated by the FDA and are equivalent to brand-name (innovator) medicines. If this shortage affects your patients, we recommend discussing alternative options within your teams to devise a management strategy.
The American Society of Nephrology (ASN) Department of Policy and Public Affairs team has received numerous questions from interested members and from the broader kidney community on the recent
Executive Order on Advancing American Kidney Health
and the accompanying
Department of Health and Human Services report
highlighting specific initiatives. In order to engage with our members, we will be running a series in Kidney News Online that addresses these questions. This is the first piece in that series.
